M. Al-Mahtab1, M. Bazinet2, A. Vaillant2*
1Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, 2REPLICor Inc., Montreal, QC, Canada. *[email protected]
Background: HBsAg plays a role in suppressing the immune system and may allow maintenance of chronic liver infection. REP 9AC inhibits the release of HBsAg from infected hepatocytes. In preclinical studies surface antigen seroclearance occurred after two weeks of treatment and four weeks of treatment resulted in 55% of animals achieving a durable SVR. REP 9AC is currently being evaluated in patients with chronic HBV in a proof of concept clinical trial. An updated report on interim clinical trial data will be presented.
Methods: Patients were HBsAg+ with pre-treatment HBV DNA titers between 106 and 1012 copies/ml and had significant liver fibrosis. Safety and virologic response (HBV DNA, HBsAg, anti-HBs) were assessed at the trial site and by confirmatory testing (HBsAg, HBeAg, anti-HBs, anti-HBe) of frozen serum samples using the Architect ™ testing platform.
Results: At the time of abstract submission, 5 of 8 patients treated have cleared serum HBsAg as early as 7 days and no later than 15 weeks following initiation of treatment at higher doses. Anti-HBsAg antibodies have been observed in 7 out of 8 patients. Six, patients have achieved a 3 to 7 log reduction in their HBV DNA titers from pre-treatment levels after 7-13 weeks of treatment and three of these patients have achieved complete control of their infection after 20-27 weeks of treatment (HBV DNA -, HBsAg -, HBeAg -, anti-HBs +, anti-HBe +) and are being followed off treatment. These 3 patients are currently maintaining control over their infections 14, 27 and 52 weeks after stopping treatment.
Conclusions: REP 9AC can rapidly clear serum HBsAg in infected patients which appears to allow the restoration of an effective immune response, leading to the achievement of SVRs in three patients to date. These results suggest that REP 9AC may become an important new tool in the treatment of chronic hepatitis B.
StephenW 发表于 2011-4-3 23:26
REP9AC在欧洲肝病学会柏林2011年4月1日, 但没有新的资料.
http://www1.easl.eu/easl2011/program/Orals/ ...
欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) | Powered by Discuz! X1.5 |